Earnings per share for the last twelve months: Candel Therapeutics Inc. (CADL)
The financial stability of Candel Therapeutics (CADL) is based on the prudent allocation of clinical trial budgets and grants. The annual specific profit TTM on GURU.Markets illustrates the yield dynamics, where the current status is -1.50. Candel Therapeutics (CADL) minimizes risks by developing personalized therapy methods for brain and lung cancer. The active phase of clinical trial development confirms the high significance of innovative products in the fight against aggressive tumors.
Summary analytical data breakdowns for Candel Therapeutics (CADL)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Candel Therapeutics|CADL - Long-Term Debt to Capital|Short-Term Debt to Equity Candel Therapeutics Inc.|CADL - Company Aggregate Debt|Debts to Book Capitalization Candel Therapeutics|CADL - Company Long-Term Indebtedness|Company Short-Term Debts Candel Therapeutics|Quick Liquidity candeltx.com
- net income and valuation multiples indicators:
CADL - Company Net Income|Future Profit Candel Therapeutics|CADL - Company Value to Net Income|Projected Price to Earnings Candel|CADL - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Candel Therapeutics, Inc.|CADL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Candel Therapeutics|CADL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months candeltx.com|CADL - Earnings per share increase in current year|Earnings growth forecast for next year Candel Therapeutics
- revenue and sales proceeds data:
Fundamental valuation:Candel Therapeutics (CADL)
For Candel Therapeutics (CADL), which is developing sustainable bioethics in cancer immunotherapy, the current trailing twelve-month EPS reflects the efficiency of innovation capitalization under strict cost controls. This indicator is calculated by dividing the total annual net income by the number of shares outstanding, allowing investors to assess the real return on a single share of the business and compare profit growth rates with the market price.
Direct competitors
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|ARAY (accuray.com) - Net earnings per share for the last 12 months|SELLAS Life Sciences Group Inc. (SLS) - Net earnings per share (EPS TTM)|ACTU (Actuate Therapeutics Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Citius Oncology Inc|Net earnings per share (EPS TTM) HURA|TARA (Protara Therapeutics) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) FATE (Fate Therapeutics)|Net earnings per share for the last four quarters Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Net earnings per share (EPS TTM)|CSBR (Champions Oncology, Inc.) - Earnings per share for the last 12 months|XBIT (XBiotech USA) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Radiopharm Theranostics (RADX)|Net earnings per share for the last 12 months ARTV (Artiva Biotherapeutics, Inc.)|ANL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Veru Inc. VERU|Earnings per share for the trailing year TPST|XLO: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Renovaro RENB|MURA (muraloncology.com) - Net earnings per share for the last 12 months|Kairos Pharma Inc - Earnings per share for the trailing year|Net earnings per share for the last 12 months OKUR|Net earnings per one share for the last twelve months CytoMed Therapeutics Limited GDTC|Net earnings per share (EPS TTM) CRIS|Net earnings per share (EPS TTM) Apollomics Inc. (APLM)|Net earnings per share (EPS TTM) THAR (Tharimmune Corp)|Net earnings per share for the last four quarters Advanced Biomed Inc (ADVB)|Genprex Inc - Net earnings per share (EPS TTM)|CLDI - Net earnings per share (EPS TTM)|Sunshine Biopharma Inc. (SBFM) - Earnings per share for the last twelve months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
